參考資料

1. 1
   Awadasseid, A., Hou, J., Gamallat, Y., Xueqi, S., Eugene, K. D., Musa Hago, A., ... & Xin, Y. (2017). PloS one, 12(2), e0171270.
2. 2
   Chu K. K. W. ,Chow A. H. L. (2006) United States patent filing : US7,048,932B2
3. 3
   Chu K. K. W. ,Ho S. S. S. , Chow A. H. L. (2002 J Clin Pharmacol, 42(9):976-84
4. 4
   Habtemariam, S. (2020). Biomedicines, 8(5), 135.
5. 5
   Hor, S. Y., Ahmad, M., Farsi, E., Lim, C. P., Asmawi, M. Z., & Yam, M. F. (2011). Journal of ethnopharmacology, 137(3), 1067–1076. https://doi.org/10.1016/j.jep.2011.07.007
6. 6
   Internal Research of comparison between different coriolus versicolor products in response to in vitro mitogenic activity
7. 7
   King-Fai Cheng, Ping-Chung Leung (2008)
8. 8
   Kohgo Y, Hirayama Y, Sakamaki S, Matsunaga T, Ohi S, Kuga T, Kato J, Niitsu Y. Acta Haematol. 1994;92(3):130-5. doi: 10.1159/000204202. PMID: 7532894.
9. 9
   Kariya K, Nakamura K, Nomoto K, Matama S, Saigenji K. Molecular Biotherapy. 1992 Mar;4(1):40-46.
10. 10
    Lam CS, Cheng LP, Zhou LM, Cheung YT, Zuo Z. Chin Med. 2020 Jul 25;15:75. doi: 10.1186/s13020-020-00356-4. PMID: 32724333; PMCID: PMC7382813.
11. 11
    Lau, A. S. Y., Yang, L. H. C., & Chik, S. C. C. (2018). U.S. Patent No. 9,861,604. Washington, DC: U.S. Patent and Trademark Office.
12. 12
    Leung M.Y.K., Liu C., Koon J.C.M., Fung K.P. (2006) Immunology Letters 105 : 104-14
13. 13
    Liu F., Ooi V.E.C., Fung M.C. (1999) Life Sci. 64(12) : 1005-11
14. 14
    Luo, Ke-Wang (2014)
15. 15
    Luo, K. W., Yue, G. G., Ko, C. H., Lee, J. K., Gao, S., Li, L. F., Li, G., Fung, K. P., Leung, P. C., & Lau, C. B. (2014Phytomedicine : international journal of phytotherapy and phytopharmacology, 21(8-9), 1078–1087. https://doi.org/10.1016/j.phymed.2014.04.020
16. 16
    M Toi et al.1992.
17. 17
    Ohwada S., Ogawa T., Makita F., Tanahashi F., Ohya T., Tomizawa N., Satoh Y., Kobayashi I., Izumi M., Takeyoshi I., Hamada K., Minagushi S., Togo Y., Toshihiko T., Koyama T., Kamio M (2006)
18. 18
    Roca-Lema, D., Martinez-Iglesias, O., Fernández de Ana Portela, C., Rodríguez-Blanco, A., Valladares-Ayerbes, M., Díaz-Díaz, A., Casas-Pais, A., Prego, C., & Figueroa, A. (2019). International journal of medical sciences, 16(2), 231–240. https://doi.org/10.7150/ijms.28811
19. 19
    Saleh, M. H., Rashedi, I., & Keating, A. (2017). Frontiers in immunology, 8, 1087.
20. 20
    T.B. Ng, , General Pharmacology: The Vascular System, Volume 30, Issue 1, 1998, Pages 1-4, ISSN 0306-3623, https://doi.org/10.1016/S0306-3623(97)00076-1.
21. 21
    Takahashi, Y., Mai, M., & Nakazato, H. (2005).
22. 22
    Toge, T., Kegoya, Y., Yamaguchi, Y., Baba, N., Kuninobu, H., Takayama, T., Yanagawa, E., & Hattori, T. (1989).
23. 23
    Tsukagoshi S., Hashimoto Y., Fugii G., Kabayashi H., Namoto K., Orita K. (1984)
24. 24
    Wong L. Y. Eliza, Cheng K. F. , Leung P. C. (2012) Recent Patents on Inflammation & Allergy Drug Discovery 6:78-87
25. 25
    Wong, L. Y. E., Wong, C. K., Leung, P. C., & Lam, W. K. C. (2010). Patient preference and adherence, 4, 223.
26. 26
    Yamashita K., Ougolkov A.V., Nakazato H., Ito K., Ohashi Y., Kitakata H., Yasumoto K., Omote K., Mai M., Takahashi Y., Minamoto T. (2007) Dis Colon Rectum 50 : 1169-81
27. 27
    Zhou Y.L., Hua J., Lin J., Tang K.X. (2007) Afr J. Biotechnol 6 : 1740-43
28. 28
    Zhou, X., Jiang, H., Lin, J., & Tang, K. (2007). African Journal of Biotechnology, 6(15).
29. 29
    Zhong Y., Zou J., Zhang L.Y. (2001) Journal of Traditional Chinese Medicine 28 : 668-9
30. 30
    Treatments such as chemotherapy, radiotherapy, immunotherapy etc. are required to weaken abnormal cells before immune cells are able to eliminate them - The immune system itself cannot eliminate abnormal cells on its own
31. 31
    Oncozac®'s only ingredient ONCO-Z® is the dietary ingredient verified by the United States Pharmacopeial Convention.